Early Answers, Better Outcomes: How Cx Precision Medicine Is Rethinking Alzheimer's Diagnosis From the Ground Up

In this episode of the StartUp Health NOW Podcast, Unity Stokes interviews Denguele Altman, CEO of CX Precision Medicine, about groundbreaking advancements in early diagnosis for Alzheimer's and Parkinson's diseases. The conversation centers on CX Precision Medicine's mission to transform neurodegenerative disease diagnostics by empowering primary care physicians with accessible, AI-driven blood tests—specifically their NeuroFirst Memory test—that can rule out Alzheimer’s early, cutting the current average 3.5-year diagnostic delay. Altman emphasizes that early triage not only accelerates access to effective treatments but also provides critical peace of mind for patients and reduces unnecessary, costly specialty referrals. The company is also advancing a similar test for Parkinson’s and exploring future precision diagnostics for Alzheimer’s subtypes. Altman shares optimism about the convergence of AI, genomics, and scalable lab platforms to drive down costs and democratize access, even as reimbursement challenges persist. With a planned beta launch within 12 months and a Series A funding round underway, CX Precision Medicine is positioned at the forefront of a paradigm shift in neurodegenerative care. Key takeaways include: 1) Early triage via blood-based tests can cut diagnostic timelines from years to weeks, preserving treatment windows; 2) Ruling out Alzheimer’s early prevents unnecessary anxiety and redirects care toward treatable conditions like sleep apnea or menopause; 3) AI-powered, multiplexed immunoassays enable scalable, low-cost testing at scale; 4) The future of precision medicine lies in integrating clinical, genetic, and proteomic data across healthcare silos; 5) Patient-driven demand for early screening—evidenced by high uptake of out-of-pocket tests like Grail’s Galeri—signals a growing market for accessible diagnostics. The episode closes with a call to action for investors, innovators, and healthcare stakeholders to join the movement toward early, equitable, and outcome-driven neurodegenerative care.